NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $998 | -99.8% | 1,676 | -99.8% | 0.00% | -100.0% |
| Q2 2023 | $429,684 | -67.8% | 747,276 | -60.7% | 0.00% | -66.7% |
| Q1 2023 | $1,336,251 | -68.1% | 1,900,784 | +2.6% | 0.00% | -75.0% |
| Q4 2022 | $4,187,554 | +56.3% | 1,852,900 | +121.4% | 0.01% | +50.0% |
| Q3 2022 | $2,680,000 | +553.7% | 837,065 | +675.2% | 0.01% | +700.0% |
| Q2 2022 | $410,000 | +11.4% | 107,978 | +427.6% | 0.00% | 0.0% |
| Q3 2021 | $368,000 | -1.6% | 20,466 | -6.0% | 0.00% | 0.0% |
| Q2 2021 | $374,000 | -27.7% | 21,770 | -15.7% | 0.00% | 0.0% |
| Q1 2021 | $517,000 | +17.0% | 25,837 | -0.6% | 0.00% | 0.0% |
| Q4 2020 | $442,000 | -12.3% | 26,000 | -14.5% | 0.00% | 0.0% |
| Q3 2020 | $504,000 | -51.6% | 30,406 | -32.4% | 0.00% | -66.7% |
| Q2 2020 | $1,041,000 | -54.6% | 44,969 | -65.0% | 0.00% | -57.1% |
| Q1 2020 | $2,292,000 | -89.6% | 128,442 | -87.5% | 0.01% | -85.7% |
| Q4 2019 | $22,115,000 | -21.8% | 1,024,531 | -34.0% | 0.05% | -29.0% |
| Q3 2019 | $28,272,000 | +11930.6% | 1,552,100 | +23445.2% | 0.07% | +6800.0% |
| Q2 2019 | $235,000 | +4.9% | 6,592 | -0.9% | 0.00% | 0.0% |
| Q1 2019 | $224,000 | +5.2% | 6,655 | +2.7% | 0.00% | 0.0% |
| Q4 2018 | $213,000 | -98.9% | 6,483 | -98.0% | 0.00% | -97.9% |
| Q3 2018 | $20,059,000 | +24.8% | 329,054 | -0.0% | 0.05% | 0.0% |
| Q2 2018 | $16,074,000 | -73.2% | 329,188 | -41.6% | 0.05% | -73.0% |
| Q1 2018 | $59,941,000 | -21.6% | 564,101 | -55.9% | 0.17% | -19.4% |
| Q4 2017 | $76,424,000 | +209.7% | 1,279,713 | +24.5% | 0.22% | +204.2% |
| Q3 2017 | $24,677,000 | +14.9% | 1,028,200 | -6.4% | 0.07% | +14.5% |
| Q2 2017 | $21,485,000 | -15.2% | 1,099,000 | +1.8% | 0.06% | -13.9% |
| Q1 2017 | $25,326,000 | +101.5% | 1,079,100 | +5.3% | 0.07% | +89.5% |
| Q4 2016 | $12,568,000 | -28.6% | 1,024,300 | 0.0% | 0.04% | -25.5% |
| Q3 2016 | $17,597,000 | -32.0% | 1,024,300 | -43.7% | 0.05% | -32.0% |
| Q2 2016 | $25,868,000 | +4.8% | 1,817,803 | +1.3% | 0.08% | -2.6% |
| Q1 2016 | $24,682,000 | -62.2% | 1,795,063 | -53.7% | 0.08% | -62.8% |
| Q4 2015 | $65,360,000 | +66.4% | 3,878,921 | +8.2% | 0.21% | +63.0% |
| Q3 2015 | $39,276,000 | -12.2% | 3,583,580 | +0.2% | 0.13% | -5.2% |
| Q2 2015 | $44,747,000 | -4.3% | 3,576,900 | -15.8% | 0.13% | -5.6% |
| Q1 2015 | $46,745,000 | -39.5% | 4,249,572 | -14.8% | 0.14% | -40.6% |
| Q4 2014 | $77,271,000 | +9.0% | 4,985,200 | -15.1% | 0.24% | +4.8% |
| Q3 2014 | $70,865,000 | -6.5% | 5,871,200 | -0.7% | 0.23% | -4.2% |
| Q2 2014 | $75,777,000 | -2.1% | 5,910,834 | -7.4% | 0.24% | -8.1% |
| Q1 2014 | $77,374,000 | +29.8% | 6,384,000 | +21.6% | 0.26% | +25.7% |
| Q4 2013 | $59,595,000 | +5.6% | 5,250,637 | -2.7% | 0.21% | -5.1% |
| Q3 2013 | $56,417,000 | -21.8% | 5,398,770 | -13.6% | 0.22% | -24.1% |
| Q2 2013 | $72,170,000 | – | 6,248,500 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |